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Abstract
Previous study from our group has pointed out a lower number of cardiovascular (CV) events in Italian patients with systemic lupus
erythematosus (SLE) than in North European and American ones. This study aims to assess the incidence of the ﬁrst CV event in a
large, multicenter, Italian cohort of patients with SLE and search for differences in disease and traditional risk factors among distinct
cohorts.
Clinical charts of SLE patients consecutively admitted to 5 Italian rheumatologic centers from November 1st 2000 to December
31st 2015 and free of CV events at baseline were retrospectively studied. CV cumulative incidence (ie, the proportion of patients who
experienced a new CV event over the follow-up period) and CV incidence rate (ie, the number of events in the cohort divided by the
total number of years at risk) were evaluated. The detected incidences were compared with those reported in SLE cohorts from other
countries.
The median duration of follow-up was 6 years (IQR=3–11). During the observational period, 37 (cumulative incidence=7.2%)
patients had a ﬁrst episode of CV event with an incidence rate of 10.1/1000 person-years. The CV cumulative incidence and
incidence rate detected in our Italian cohort were lower than those from most North European and American cohorts, characterized
by a high impact of traditional risk factors. Nevertheless, the cumulative incidence was similar to that reported in a Spanish cohort with
a high frequency of traditional risk factors (geographic impact), while the incidence rate was only slightly higher than that in the
Baltimore cohort, which is characterized by a strict follow-up of patients (medical impact).
Our results conﬁrmed that Italian lupus patients have a low incidence of CV events. Moreover, the geographic origin, traditional risk
factors, and medical approach appear to have an impact on CV disease in SLE.
Abbreviations: ACR = American College of Rheumatology, aPL = antiphospholipid antibody, ASA = aspirin, CV =
cardiovascular, HCQ = hydroxychloroquine, SCORE = Systematic COronary Risk Evaluation, SLE = systemic lupus erythematosus.
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Systemic lupus erythematosus (SLE) is a heterogeneous chronic
autoimmune disease that has an important impact on life
expectancy.[1] Currently, effective management of active disease
manifestations has improved the survival rate in patients with
SLE. As a consequence, the mortality pattern has changed in
recent years and, nowadays, cardiovascular (CV) disease is the
leading cause of premature death among SLE patients.[2,3]
We have recently explored the role of traditional and disease-
related CV risk factors and aspirin (ASA)±hydroxychloroquine
(HCQ) treatment in the occurrence of CV events in patients
with SLE.[4–6] We detected that ASA treatment and HCQ use for
more than 5 years were protective against thrombosis. Moreover,
patients with a ﬁrst CV event compared with those without any
thrombotic events were antiphospholipid antibody (aPL) positive
and had signiﬁcantly higher disease damage, higher blood
pressure, and hypercholesterolemia.
Looking at data from these studies, we were impressed by the
low incidence of CV events in our SLE cohort. Over the last
decades, several studies have analyzed the incidence of CV events
in SLE patients. However, the majority of them have been
conducted in American[7–9] and North European countries.[10,11]
In that regard, geography and ethnic background might play a
role. Actually, the only available study from Mediterranean
countries[12] has pointed out a lower incidence of CV events in
Spanish patients with respect to those from North Europe and
America.
At the best of our knowledge, no studies have considered
cumulative incidence and incidence rate of CV events in Italy. The
present study is devoted to estimate the incidence of a ﬁrst ever
CV event in Italian lupus patients from 5 rheumatologic tertiary
units from North, Centre, and South Italy.2. Materials and methods
2.1. Patients and study design
Consecutive adult patients with SLE seen at the 5 Italian
participating centers from November 1st 2000 to December 31st
2015 were considered for the study. Centers were widely
distributed across the country (1 from North, 2 from Center, and
2 from South Italy). Patients were enrolled if, at admission, 1997
updated American College of Rheumatology (ACR) criteria for
SLE[13] and/or the 2012 classiﬁcation criteria of the Systemic
Lupus International Collaborating Clinics group[14] were satis-
ﬁed and no CV event had been previously experienced.
The follow-up started at the ﬁrst visit and ended at the time of
the ﬁrst CV event, or death or at the last observation in patients
who did not experience any thrombotic event. Written informed
consent was obtained by each patient. The study was approved
by local Ethics Committees (CE 278\17).2.2. Clinical and laboratory data collection
Data recorded included demographics, clinical features, exposure
to drugs, and serologic investigations carried out to assess disease
activity by the Safety of Estrogens in Lupus Erythematosus
National Assessment SLE Disease Activity Index[15] and disease
damage by the Systemic Lupus International Collaborating
Clinics group/ACR damage Index (SDI).[16] Antinuclear and anti-
dsDNA antibodies were detected by immunoﬂuorescence using
HEp-2 cells and Crithidia luciliae as substrate[17]; aPL positivity
was deﬁned when at least one of the following was detected at2medium-high titers on 2 or more occasions at least 12 weeks
apart: lupus anticoagulant, anticardiolipin, and anti-b2 glyco-
protein I antibodies (IgG and IgM).
The following traditional CV risk factors were registered:
smoking status, dyslipidemia (low-density lipoprotein >120mg/
dL and/or triglycerides >150mg/dL and/or intake of lipid-
lowering drugs), diabetes (2 fasting serum glucose levels >126
mg/dL and/or antidiabetic drugs), arterial hypertension (blood
pressure ≥130e/o 85mmHg on 2 occasions and/or intake of
antihypertensive drugs), and obesity (BMI>30) and were
considered to be present if they were observed at any time
during the follow-up period.[17] Systematic COronary Risk
Evaluation (SCORE), using the charts of low risk European
countries, was assessed to assign patients to the appropriate 10
year-risk category at baseline.[18]
According to the ACR guidelines for referral and management
of SLE,[19] each patient was subclassiﬁed as severe if any of the
following conditions had occurred at baseline: peripheral or
central nervous system disease (eg, psychosis, confusion,
disorientation, paresthesias, seizure, cognitive dysfunction,
severe unremitting headache, and retinal vasculitis), glomerulo-
nephritis, heart and lung parenchymal manifestations, hemolytic,
or aplastic anemia. Moreover, treatments with ASA, HCQ, and/
or statins were recorded.2.3. Outcome variables
Patients were assessed every 6 months, unless requiring more
frequent visits for their clinical condition. At each visit, any
intervening CV event was recorded.
A CV event was deﬁned as the presence of at least one of the
following[20]:(1) Ischemic heart disease, including angina pectoris (conﬁrmed
by exercise stress test) or MI (conﬁrmed by electrocardiogra-
phy and cardiac enzymes).
Ischemic cerebrovascular disease, including transient ische-(2)
mic attack or stroke supported by an imaging procedure (ie,
computed tomography angiography or magnetic resonance
angiography).
Ischemic peripheral vascular disease: intermitted claudication(3)
or peripheral arterial thrombosis, conﬁrmed by an imaging
procedure (angiography or Doppler ﬂow studies).
Patients with any CV event occurred prior to the ﬁrst visit were
excluded.2.4. CV event incidence
Cumulative incidence (ie, the proportion of patients who
experienced a new CV event over the follow-up period) and
incidence rates (ie, the number of events observed divided by the
total number of person-years at risk, expressed as n/1000 person-
years of observation) of all and each CV event were calculated.
Data from the Italian registry Progetto Cuore[21] were used to
compare the incidence of ischemic coronary and cerebral events
observed with those of the Italian general population. Moreover,
the detected incidences were compared with those reported in
other European (Spanish and Swedish)[10–12] and American
(from Maryland, Alabama, and Wisconsin)[7–9] SLE cohorts in
which the respective item had been evaluated. In addition,
baseline characteristics and traditional risk-factors between
patients with and without CV events and among the distinct
cohorts were compared.
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Continuous variables are presented as the mean±SD if normally
distributed or as median and quartiles (IQR) if distribution was
skewed. Continuous variables were analyzed with Student
unpaired t test or with the Mann–Whitney U test as appropriate.
The Chi-square test or Fisher exact test was applied for
categorical variables. Cox regression analysis was carried out
to identify factors independently associated with CV event
occurrence. A P value <.05 was considered signiﬁcant. MedCalc
software, version 15.4, was used for all analyses.
3. Results
3.1. Baseline data
Table 1 lists the main epidemiological, serological, and clinical
features of the 507 patients considered in the present study. Most
(92.8%) were women, with a median (IQR) age at study entry of
39 (31–49) years, a median SLEDAI of 2 (IQR 0–4), and a
median SDI of 0 (IQR 0–0). High levels of total serum cholesterol
and triglycerides were observed in 74 (14.5%) and 37 (7.2%)
patients, respectively. Fifty-nine patients (11.6%) had a body
mass index >30 and 135 (26.6%) had smoked before their entry
into the study. Arterial hypertension was detected in 101 (19.9%)
patients, while type II diabetes mellitus in 16 (3.1%) patients.
Two hundred and forty-six patients (48.5%) had a severe disease
and 137 (27%) were aPL positive. Median SCORE index was
0% (0–1). A total of 302 (59.5%) patients was treated with ASA:Table 1
Baseline characteristics of patients (values in bold are statistically s
All patients N=507 Patients who devel
Traditional risk factors
Male gender (n, %) 36 (7.1%) 6
Age, y (median, IQR) 39 (31–49) 45
Smokers (n, %) 135 (26.6%) 14
Obesity (n,%) 59 (11.6%) 7
Hypertension (n, %) 101 (19.9%) 20
Hypercholesterolemia (n, %) 74 (14.5%) 12
Hypertriglyceridemia (n, %) 37 (7.2%) 5
Diabetes (n, %) 16 (3.1%) 2
SCORE (median, IQR) 0 (0–1) 0
Lupus manifestations
Severe SLE (n, %) 174 (34.3%) 13
Nephritis (n, %) 106 (20.9%) 6
Neurological disorders (n, %) 49 (9.6%) 8
Lung involvement (n, %) 13 (2.5%) 2
Haemolytic anaemia (n, %) 49 (9.6%) 4
SELENA-SLEDAI (median, IQR) 2 (0–4) 2
SDI, (median, IQR) 0 (0-0) 0
Autoantibody proﬁle
Any aPL (n, %) 137 (27.0%) 16
CL IgG–IgM (n, %) 104 (20.5%) 12
b2GP-1IgG–IgM (n, %) 75 (14.7%) 9
LAC (n, %) 81 (15.9%) 12
dsDNA (n, %) 225 (44.3%) 15
Sm (n, %) 61 (12.0%) 3
Treatments
Hydroxychloroquine (n, %) 431 (85.0%) 26
Aspirin (n, %) 302 (59.5%) 17
Statins (n, %) 60 (11.8%) 3
aPL= antiphospholipid antibody, CL= cardiolipin, CV= cardiovascular, dsDNA=doublestranded DNA, b
Systematic COronary Risk Evaluation, SDI=Systemic Lupus International Collaborating Clinics/American
Estrogens in Lupus Erythematosus National Assessment SLE Disease Activity Index), SLE= systemic lup
3258 (50.8%) patients received both ASA and HCQ, whereas 44
(8.6%) received ASA alone. A total of 173 (34.1%) patients were
treated with HCQ alone and 32 (6.3%) patients received neither
ASA nor HCQ.3.2. CV events
The median duration of follow-up was 6 years (IQR=3–11) with
a total of 3659 person-years. Thirty-seven patients (cumulative
incidence=7.2%) had a ﬁrst CV event with an incidence rate of
10.1/1000 person-years. No difference was detected in the
cumulative incidence neither in the incidence rate of the ﬁrst CV
events among patients from North, Centre, and South Italy.
Therefore, patients were collectively analyzed.
The average (±SD) age at the ﬁrst CV event was 47 (±13) years
and the event occurred after a median follow-up of 5.6 years.
Ischemic heart disease was the most frequent CV event (21/37;
56.7%) with an incidence rate of 5.7/1000 person-years,
followed by ischemic cerebrovascular disease (11/37; 29.7%;
3.0/1000 person-years) and ischemic peripheral vascular disease
(5/37; 13.5%; 1.3/1000 person-years).3.3. Predictors of CV events
Table 1 also shows the characteristics of SLE patients who had
CV events compared with all other patients. Subjects who
developed a ﬁrst CV event were mostly male, had a higher
prevalence of arterial hypertension, high cholesterol levels,igniﬁcant at an alpha of .05).
oped a CV event N=37 Patients free of CV events N=470 P
(16.2%) 30 (6.3%) .025
(35–53) 39 (31–49) >.05
(37.8%) 121 (25.7%) >.05
(18.9%) 52 (11.0%) >.05
(54.0%) 81 (17.2%) <.0001
(32.4%) 62 (13.1%) .001
(13.5%) 32 (6.8%) >.05
(5.4%) 14 (2.9%) >.05
(0–1) 0 (0–1) >.05
(35.1%) 161 (34.2%) >.05
(16.1%) 100 (21.2%) >.05
(21.6%) 41 (8.7%) .010
(5.4%) 11 (2.3%) >.05
(10.8%) 45 (9.5%) >.05
(0–4) 2 (0–4) >.05
(0-0) 0 (0-0) >.05
(43.2%) 121 (25.7%) .021
(32.4%) 92 (19.5%) >.05
(24.3%) 66 (14.0%) >.05
(32.4%) 69 (14.6%) .004
(40.5%) 210 (44.6%) >.05
(8.1%) 58 (12.3%) >.05
(70.2%) 405 (86.1%) .009
(45.9%) 285 (60.6%) .07
(8.1%) 57 (12.1%) >.05
2GP-1=beta2glykoprotein-1, IQR= interquartile range, LAC= lupus anticoagulant test, SCORE=
College of Rheumatology Damage Index, SELENA-SLEDAI=SLE Disease Activity Index (Safety of
us erythematosus, Sm=Smith.
Table 2
Incidence rates (per 1000 person-years) and rates ratio for CV events stratiﬁed by sex and age.
Male Female
CV events/
person-years, n
Incidence rate
(95% CI)
Incidence rate ratio
general population (95% CI) P
CV events/
person-years, n
Incidence rate
(95% CI)
Incidence rate ratio
general population (95% CI) P
<45y 1/89 11.3 (0.2–63.2) 2.9 (2.0–4.4) <.001 14/1516 9.2 (5.0–15.4) 11.5 (5.5–27.4) <.001
45–54y 1/52 19.6 (2.8–36.1) 3.1 (2.3–4.2) <.001 9/988 9.1 (5.7–10.8) 5.0 (3.0–8.9) <.001
>55y 4/102 39.0 (10.6–99.8) 2.6 (2.2–3.2) <.001 7/822 8.5 (3.4–17.5) 1.6 (1.1–2.4) .003
CI= conﬁdence interval, CV= cardiovascular.
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patients treated with ASA and HCQ had a lower incidence of CV
events. At stratiﬁed analyses, there was statistically signiﬁcant
effect modiﬁcation by sex and age. Although the absolute rate
was highest among the oldest males (for age group >55 years),
the relative incidence rate was highest for females <45 years old
compared with the general population matched for age and sex
(Table 2). At univariate analysis (Table 3), patients with a ﬁrst CV
event compared with those without any thrombotic events were
smokers, had signiﬁcantly higher blood pressure, higher SCORE
index, and BMI (P= .026, P= .001, P< .0001, an P= .049,
respectively). Of SLE manifestations, aPL positivity, higher
disease damage at last visit, and neurolupus were more frequently
observed in patients with CV disease (P= .005, P= .01, and
P= .005, respectively). Moreover, ASA treatment (P= .038) and
HCQ use (P= .001) were negative predictors. All other variables
examined, including statins, hypercholesterolemia, hypertrigly-
ceridemia, diabetes mellitus, disease activity at ﬁrst and last visit,Table 3
Factors predicting the occurrence of a ﬁrst cardiovascular event
during follow-up in univariate analysis (values in bold are
statistically signiﬁcant at an alpha of .05).
Features P value Hazard ratio 95% CI
High cumulative steroids dose .203 1.52 0.79–2.92
Hypertension (ever) .001 3.04 1.52–6.06
aPL positivity (ever) .005 2.54 1.31–4.89
CL IgG–IgM .0009 2.98 1.56–5.70
b2GP-1 IgG–IgM .002 2.84 1.46–5.52
LAC .003 2.66 1.39–5.08
Cumulative damage at ﬁrst visit .411 0.90 0.69–1.15
Cumulative damage at last visit .010 1.40 1.08–1.83
Smoke (ever) .026 2.04 1.08–3.86
Hypercholesterolemia (ever) .092 1.74 0.91–3.32
Obesity (ever) .049 1.99 1.01–3.98
Hypertriglyceridaemia (ever) .087 1.92 0.90–4.08
Diabetes mellitus (ever) .198 1.97 0.69–5.58
Severe SLE (ever) .800 1.08 0.56–2.08
Haemolytic anaemia .318 1.52 0.66–3.46
Neurological disorders .005 2.59 1.32–5.10
Lung involvement .827 0.85 0.20–3.54
Nephritis .274 0.67 0.33–1.36
SLEDAI ﬁrst visit .081 1.05 0.99–1.12
SLEDAI last visit .427 1.03 0.94–1.12
SCORE index <.0001 1.89 1.39–2.56
Aspirin .038 0.50 0.26–0.96
Hydroxychloroquine .001 0.32 0.16–0.66
Statins .336 0.56 0.17–1.82
aPL= antiphospholipid antibody, CL= cardiolipin, b2GP-1=beta2glykoprotein-1, LAC= lupus
anticoagulant test, SCORE=Systematic COronary Risk Evaluation, SDI=Systemic Lupus International
Collaborating Clinics/American College of Rheumatology Damage Index, SELENA-SLEDAI=SLE
Disease Activity Index (Safety of Estrogens in Lupus Erythematosus National Assessment SLE Disease
Activity Index), SLE= systemic lupus erythematosus.
4baseline disease damage, other severe SLE manifestations, were
not associated, either positively or negatively, with the occurrence
of CV events. At a multivariable Cox regression model (Table 4),
aPL positivity (HR 4.77, 95% CI 2.26–10.08), smoking (HR
2.49, 95% CI 1.23–5.01), and hypertension (HR 2.50, 95% CI
1.16–5.37) were independent predictors of the ﬁrst CV event,
while taking ASA and HCQ was protective against thrombosis
(HR 0.28, 95% CI 0.13–0.57, and HR 0.23, 95% CI 0.11–0.50,
respectively).3.4. Comparison with general population
To compare the CV ischemic morbidity in our cohort with that
expected in a sample of the Italian population matched for age
and traditional risk factors, we calculated the expected 10-year
incidence rate of CV events in our patients according to the risk
score from Progetto Cuore.[21] Rate of ischemic events observed
in our SLE cohort was 12-fold higher than that expected in the
age and sex-matched Italian population (0.8/1000 person-years;
P< .0001).3.5. Comparison with other lupus cohorts
We compared baseline characteristics, CV cumulative incidence,
and incidence rates detected in our cohort with those from other
European (Spanish and Swedish)[10–12] and American (from
Maryland, Alabama, and Wisconsin)[7–9] cohorts (Table 5).
Signiﬁcant differences were detected in the prevalences of males,
smokers, hypertensive, and hypercholesterolemic patients. In
particular, cohorts from Spain and Sweden had a high prevalence
of smoking (P< .0001), hypertension (P< .0001), and dyslipi-
demia (P= .0002). Patients from Wisconsin cohort were more
likely to smoke (P< .0001), while patients from Alabama cohort
were more likely to present hypertension (P< .0001). Males wereTable 4
Factors predicting the occurrence of a ﬁrst cardiovascular event
during follow-up in multivariable analysis (values in bold are
statistically signiﬁcant at an alpha of .05).
Features P Hazard ratio 95% CI
Hypertension .018 2.50 1.16–5.37
aPL positivity <.0001 4.77 2.26–10.08
Cumulative damage at last visit .375 1.15 0.83–1.60
Smoke .010 2.49 1.23–5.01
Obesity .966 0.96 0.45–2.07
Neurolupus .067 1.96 0.95–4.03
SCORE index at baseline .29 0.73 0.41–1.29
Aspirin .0005 0.28 0.13–0.57
Hydroxychloroquine .0002 0.23 0.11–0.50
aPL=antiphospholipid antibodies, CI= conﬁdence interval, SCORE=Systematic COronary Risk
Evaluation.
[12]
Table 5
Comparison of characteristics among patients from different SLE cohorts (values in bold are statistically signiﬁcant at an alpha of .05).
Our cohort N=507 Spain[12] N=3649 Sweden[10] N=182 Maryland[7] N=1874 Alabama[8] N=1333 Wisconsin [9]N=70
Male gender (n, %) 36 (7.1%) 353 (9.7%) 18 (10%) 136 (7.2%) 127 (9.6%) 13 (18.5%)
Age, y
(median, IQR) 39 (31–49) 45 (35–56) 45 (31–53) – – 52
(mean, SD) 45, 12.6 – – 37,12 35.7,12.3 –
Etnicity
White European (n, %) 507 3300 (90.4%) 171 (94%) 0 0
White Americans (n, %) 0 185 (5.1%) 0 640 (46.5%) 68 (97%)
Black n, %) 0 8 (0.2%) 0 472 (35.6%) 0
Asians (n, %) 0 21 (0.6%) 11 (6%) 0 0
Hispanics (n, %) 0 0 0 241 (18.1%) 0
Other (n, %) 0 29 (0.8%) 0 0 2 (3%)
Smokers (n, %) 135 (26.6%) 1350 (37%) 92 (51%) 215 (16.1%) 37 (52.9%)
Hypertension (n, %) 101 (19.9%) 1061 (29.1%) 54 (30%) 687 (51.5%) 17 (24%)
Dyslipidemia (n, %) 111 (21.8%) 1100 (30.1%) – – 9 (13%)
Diabetes (n, %) 16 (3.1%) 1086 (29.8%) 4 (2%) – 5 (7%)
HCQ (n, %) 431 (85%) 2878 (78.9%) 52 (29%) – 1075 (80%) 52 (75%)
Aspirin (n, %) 302 (59.5%) 1091 (29.9%) 34 (19%) – 382 (28.6%) –
Events (n, %) 37 (7%) 269 (7.4%) 24 (13%) 134 (7%) 123 (9.8%) 17 (24%)
First CV event Yes Yes Yes Yes Yes No
Mean follow-up, y 6 – 8.3 – 6.4 7.7
Person-years 3659 – – 9485 – 540
Incidence rate (1000py) 10.1 – – 14.1 – 31.4
CV= cardiovascular, HCQ=hydroxychloroquine, IQR= interquartile range, SD= standard deviation, SLE= systemic lupus erythematosus.
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cohort the majority of patients were treated with HCQ and ASA
(P< .0001).
As far as the incidence rate, because of the unavailability of
person-years follow-up in Spanish, Swedish, and Alabama
cohort, the comparison was only feasible with cohorts from
Maryland and Wisconsin. The incidence rate ratio resulted to be
signiﬁcantly higher in the Wisconsin cohort (31.4/1000 person-
years; ratio=3.11; IC95% 1.64–5.66; P< .0001) and nearly
signiﬁcantly higher in the Maryland cohort (14.1/1000 person-
years; ratio=1.39; IC95% 0.96–2.06; P.070) with respect to our
cohort (10.1/1000 person-years).4. Discussion
The present study is mainly devoted to investigate the incidence of
CV events in Italian SLE patients, to compare it with those
registered in SLE cohorts from other countries, and to search for
features associated with and potentially causative of the detected
differences.
We were moved to undergo this study by the low incidence of
CV events detected in our 3 previous studies.[4–6] Since these
studies had been mostly based on SLE cohorts from South
Italy, we enrolled patients from North, Center, and South
Italy. The present report conﬁrms the results from our previous
studies, that is, arterial hypertension and hypercholesterolemia
among traditional risk factors, aPL positivity, and neurological
involvement as disease-related factor are more frequent in
patients undergoing a ﬁrst CV event; ASA and HCQ play a
preventative role. Moreover, no difference emerged in the
cumulative incidence and incidence rates of CV events among
the 3 subgroups. Therefore, we think that our results are
generalizable to the Italian SLE population seen in outpatient care
in the last decades.
The cumulative incidence of CV events detected in our cohort
resulted to be 7.2%, which is similar to that reported in previous5studies published in other Mediterranean countries and in the
Maryland cohort,[7] but lower than those registered in other
European and American SLE cohorts,[8–10] which ranged from
9.8% to 24%. Although some differences could be due to the
varying clinical deﬁnitions used for CV events and study design,
our incidence still remained low. These disparities could be
ascribed to the differences in the prevalences of traditional risk
factors (namely, smoking, hypertension, and hypercholesterol-
emia) among the distinct cohorts and on the use in a high
percentage of our patients of ASA and HCQ. Nevertheless,
geographic and local medical factors deserve to be considered.
As far as the former, the cumulative incidence of CV events
detected in our patients was very similar to that detected in the
Spanish cohort, despite the higher frequency of traditional risk
factors and the lower prevalence of ASA-HCQ use in that cohort.
Fernández-Nebro et al[12] ascribed their results to yet undeﬁned
racial-geographical factors collectively referred to as the
“Mediterranean paradox,” by which the incidence of CV events
is dissociated from CV risk factors compared with other
industrialized countries. Such a hypothesis may, at least in part,
be consistent with our data. Actually, Mediterranean diet has
been reported to be associated with a lower incidence of CV
events in the general population.[24] Nevertheless, factors
associated with and potentially causative of the so called
“Mediterranean Paradox” in SLE patients await to be explained.
The inﬂuence of the racial background on the disease pattern in
patients with SLE has been already reported.[22] Reasons for such
signiﬁcant differences are not clear but American Black and
Hispanic patients have been shown to have an early age and
aggressive disease at onset of SLE. In addition, the risk of CV
disease was reported to be elevated among blacks, compared to
whites.[23] These aspects have been ascribed to socioeconomic
status, but race-related factors might play a role.
The lower incidence of CV events in our SLE series mirrors the
lower incidence of CV disease in the general population as
compared with Northern Europe and United States.[24,25]
Fasano et al. Medicine (2018) 97:15 MedicineNevertheless, our lupus patients were 12.5-fold more likely to
have a CV event compared with the general population,
conﬁrming the increased CV risk in SLE. In particular, the
average age at the ﬁrst CV event was 47 years, whereas in the
non-SLE population this occurred later.[26] Interestingly, al-
though younger SLE patients were at higher relative risk of CV
events compared with healthy controls, the highest rate of CV
events was observed in older male patients, suggesting that
prevention of CV complications would be important in every SLE
age group.
As far as local medical factors are concerned, the incidence rate
detected by us (10.1/1000 person-years) was only nearly
signiﬁcantly lower than that in Maryland cohort. Unlike other
cohorts, patients from Maryland undergo a strict follow-up.[7]
Actually they are examined every 3 months, which might ensue in
a better control of the main traditional risk factors and of disease
activity. However, even if disease activity indicates on-going
inﬂammation which is known to be a CV risk factor,[27] at
multivariable analysis, SLE Disease Activity Index was not
signiﬁcantly associated with CV events rates in our cohort and
only mildly associated in theMaryland cohort, after adjusting for
medication use. This is consistent with most of the previous
studies, suggesting that an isolated assessment is not enough to
identify patients at risk. However, the relatively low disease
activity at baseline in our cohort might have resulted in a limited
ability to detect the association between disease activity and the
risk of CV events.
The strengths of the present study include the homogeneity in
the ethnic composition and the large size of our sample, the long
follow-up period, the multicentric design, and the use of hard
endpoints. Moreover, no difference was detected in the incidence
of CV events among patients from North, Center, and South
Italy. This evidence suggests that the results detected in our
multicenter series reﬂect the features of the SLE Italian patient
population.
However, some limitations should be taken into account, the
main one being the retrospective design of our study, which not
allow addressing more detailed questions. In particular, this
study was not able to exclude the impact of other factors when
analyzing both the comparisons between patients with and
without CV disease and among the cohorts from different
countries. Moreover, the risk estimation from the European CV
risk algorithm SCORE, which was developed for use in the
general population, deviated from the observed risk, under-
estimating the risk of future CV events in these patients. An
explanation for the results found may be that, by design, the
SCORE is unlikely to identify young women as having a
signiﬁcant risk of CV disease. Actually, of all variables evaluated,
age and sex have an important contribution to the total risk score.
A further limitation is that, as the aPL positivity increased the CV
risk, it is possible that not all CV events recorded in our cohort
were due to atherosclerosis. However, in daily clinical practice,
sometimes it is not possible to deﬁne the etiology of each CV
event.
In conclusion, the geographic (ie, Mediterranean) origin, the
lower prevalence of traditional risk factors and the high
frequency of ASA-HCQ intake might be associated with the
low incidence rate of CV event in Italy. On the other hand, the
slight difference detected between our series and Maryland
cohort underlines the need of a strict follow-up of the SLE patient
to identify early and treat aggressively traditional risk factors,
control SLE-related risk factors and disease activity. Prospective
studies are needed to conﬁrm our ﬁndings.6Author contributions
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